{{Rsnum
|rsid=3782415
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Chromosome=12
|Orientation=minus
|Gene=SOCS2
|position=93573979
|Gene_s=SOCS2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 61.1 | 35.4 | 3.5
| HCB | 37.2 | 45.3 | 17.5
| JPT | 19.6 | 51.8 | 28.6
| YRI | 80.0 | 17.9 | 2.1
| ASW | 71.9 | 28.1 | 0.0
| CHB | 37.2 | 45.3 | 17.5
| CHD | 36.1 | 50.0 | 13.9
| GIH | 79.2 | 19.8 | 1.0
| LWK | 82.7 | 17.3 | 0.0
| MEX | 50.0 | 41.4 | 8.6
| MKK | 89.7 | 10.3 | 0.0
| TSI | 68.6 | 27.5 | 3.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=24905066
|Title=GENETIC PREDICTORS OF LONG-TERM RESPONSE TO GROWTH HORMONE (GH) THERAPY IN CHILDREN WITH GH DEFICIENCY AND TURNER SYNDROME: THE INFLUENCE OF A SOCS2 POLYMORPHISM
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}